Godavari Drugs Ltd

Godavari Drugs Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the half-year ended September 30, 2026, in accordance with SEBI’s insider trading regulations.

Godavari Drugs Limited informed BSE Limited that its Register of Members and Share Transfer Books will be closed from September 19, 2026, to September 25, 2026, for the 38th Annual General Meeting to be held on September 25, 2026, with a cut-off date of September 18, 2026, and e-voting period from September 22, 2026, at 9:00 a.m. to September 24, 2026, at 5:00 p.m.

Godavari Drugs Limited announced that its board of directors approved an alteration to the company's Memorandum of Association to include the business of nutraceuticals, dietary supplements, natural extracts, food ingredients, and allied products, subject to shareholder approval at the company's 38th Annual General Meeting on September 25, 2026. The move, required to enable the company to operate under the Food Safety and Standards Act, 2006, will take effect upon shareholder approval and filing with the Registrar of Companies, Telangana.

Godavari Drugs Limited announced that its board of directors approved an alteration to the company's Memorandum of Association to include the business of nutraceuticals, dietary supplements, natural extracts, food ingredients, and allied products, subject to shareholder approval at the company's 38th Annual General Meeting on September 25, 2026. The move, required to enable the company to operate under the Food Safety and Standards Act, 2006, will take effect upon shareholder approval and filing with the Registrar of Companies, Telangana.

Godavari Drugs Limited announced that its board approved the allotment of 7,86,690 equity shares on the conversion of an equal number of warrants to promoters, receiving Rs 5,25,11,557.50 in payment, according to a filing with the BSE Limited on August 14, 2026. The conversion increased the company’s paid-up equity capital from Rs 10,12,74,350 consisting of 1,01,27,435 equity shares to Rs 10,91,41,250 consisting of 1,09,14,125 equity shares, and the company has 15,73,375 warrants outstanding for conversion.

Godavari Drugs Limited notified the BSE Limited that it is correcting an inadvertent typographical error in its previous letter dated August 10, 2026, regarding the Board Meeting scheduled to consider and approve the unaudited financial results for the first quarter ended June 30, 2026; the correct date of the meeting is August 14, 2026, not August 24, 2026, as initially stated.

Godavari Drugs Limited will hold a board meeting on Friday, August 24, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026, along with a limited review report, according to a regulatory filing with the BSE Limited. The company closed its trading window for insiders on July 1, 2026, and it will reopen 48 hours after the financial results are declared.

Godavari Drugs announced that the 38th Annual General Meeting(AGM) of the company will be held on 25 September 2026.

Net profit of Godavari Drugs rose 44.94% to Rs 1.29 crore in the quarter ended March 2026 as against Rs 0.89 crore during the previous quarter ended March 2025. Sales rose 30.04% to Rs 33.16 crore in the quarter ended March 2026 as against Rs 25.50 crore during the previous quarter ended March 2025. For the full year,net profit declined 6.62% to Rs 4.09 crore in the year ended March 2026 as against Rs 4.38 crore during the previous year ended March 2025. Sales declined 6.65% to Rs 105.81 crore in the year ended March 2026 as against Rs 113.35 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales33.1625.50 30 105.81113.35 -7 OPM %8.8712.20 -9.7410.44 - PBDT2.132.11 1 7.138.08 -12 PBT1.521.44 6 4.705.63 -17 NP1.290.89 45 4.094.38 -7 Powered by Capital Market - Live

Godavari Drugs will hold a meeting of the Board of Directors of the Company on 27 May 2026.